Navigation Links
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
Date:6/2/2009

th fistulizing CD.
  • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
  • Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with PsA.
  • Treatment of adult patients with chronic severe plaque PsO who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

  • REMICADE is unique among available anti-TNF biologic therapies. It is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year.

    Important Safety Information

    Only a doctor can recommend a course of treatment after checking a patient's health condition. A doctor should discuss any potential benefits and risks and help make the best treatment decision on a patient by patient basis. Like other medicines that affect the immune system, REMICADE can cause serious side effects such as lowering a patient's ability to fight infections. There are reports of serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Doctors should monitor closely for signs and symptoms of TB during treatment with REMICADE. Patients should discuss any concerns about their health and medical care with their doctor.

    Patients should let their doctors know if they have or e
    '/>"/>

    SOURCE Centocor Ortho Biotech Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
    2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
    3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
    4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
    5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
    6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
    7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
    8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
    (Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
    (Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
    Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    ... SUNNYVALE, Calif. , June 22 Xoft, ... tube technology, today announced the integration of its Axxent® ... a state of the art, fully comprehensive breast center ... of breast cancer. The Pink Lotus Breast Center is ...
    ... June 22 The SCOOTER Store today announced a major ... the delivery of a power wheelchair to Earvin Thompson of ... assistance from the nation,s leading provider of power mobility equipment, will enjoy ... , , ...
    Cached Medicine Technology:Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 2Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 3The SCOOTER Store Marks Half-Millionth Life Changed 2The SCOOTER Store Marks Half-Millionth Life Changed 3The SCOOTER Store Marks Half-Millionth Life Changed 4
    (Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
    (Date:4/23/2014)... the popular Swedish children,s TV show Bolibompa, but ... new study from the University of Gothenburg explores ... as well as the link between young children,s ... Steingerdur Olafsdottir,s doctoral thesis focuses on the presence ... show Bolibompa. Healthy foods dominated in the Swedish-produced ...
    (Date:4/23/2014)... 2014 Five for-profit and non-profit organizations in ... in Proof of Concept grants to accelerate maturation ... products, the Life Sciences Discovery Fund (LSDF) announced ... Program grant to the Washington Biotechnology & Biomedical ... to train the next generation of entrepreneurs and ...
    (Date:4/23/2014)... concerned about an increase in adolescents, marijuana use following ... of relief. According to a new study at Rhode ... from states with and without medical marijuana laws, legalizing ... adolescents. The study is published online in advance of ... , "Any time a state considers legalizing medical ...
    (Date:4/23/2014)... the journal Oncotarget , explored tumour heterogeneity ... their own DNA signatures within the same cancer. ... effective, targeted treatment strategies. , Firstly they confirmed ... either the KRAS or BRAF mutation. Secondly, they ... gene mutation have that specific mutation present uniformly ...
    Breaking Medicine News(10 mins):Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
    ... Independence Day, NEW YORK, March 28 ... its website Healingstartswithus.net to create a,grassroots online network ... reach 1 million pledges by Independence Day, July ... an overflowing crowd of community,civic, social, political leaders ...
    ... Conseco, Inc. (NYSE:,CNO) announced today that it has ... ended December 31, 2007 with the Securities and Exchange,Commission., ... for 2007 was $194.0,million, compared to the $210.1 million ... results. The reported net loss applicable to,common stock for ...
    ... suffers collateral damage from blood sugar disease , , FRIDAY, ... cause of heart disease, stroke, blindness, kidney failure and ... quicker than they normally do with age, a new ... in lung function as they grow older, research published ...
    ... fever, sometimes as high as 104 or 105 degrees, and ... hospital runs test after test, specialists are brought in, but ... one knows how many go through this cyclical nightmare. ... any obvious symptoms and dont respond to antibiotics or fever ...
    ... stem cells to be engineered into new blood vessels or ... the hair on their patients heads, according to new research ... , Engineering blood vessels for bypass surgery, promoting the ... using stem cells obtained from the most accessible source -- ...
    ... Pa., March 28 Governor Edward G.,Rendell today released ... which,explains the March 31 deadline for MCare fund assessment ... I wrote informing you that the state was in ... 10 years while providing,access to affordable health care for ...
    Cached Medicine News:Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 2Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 3Health News:Conseco Files 10-K and Sets Earnings Release Date 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2
    Indications For Usage: , ,For use during pulmonary lung function testing...
    ... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
    circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
    ... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
    Medicine Products: